Cristal Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
22
Cristal Therapeutics General Information
Description
Developer of nanomedicine designed to create the next-generation targeted therapy for improving the treatment of cancer and other diseases. The company's platform offers nanomedicine centered on its proprietary polymeric nanoparticle construct that is designed to target specific tissue, cells, and intracellular components, enabling doctors, oncologists, and medical practitioners to treat cancer and other diseases effectively.
Contact Information
Website
www.cristaltherapeutics.comCorporate Office
- Oxfordlaan 55
- 6229 EV Maastricht
- Netherlands
Corporate Office
- Oxfordlaan 55
- 6229 EV Maastricht
- Netherlands
Cristal Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 7. Later Stage VC | Completed | Generating Revenue | ||||
| 6. Grant | 28-Nov-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 19-Jan-2017 | Completed | Generating Revenue | |||
| 4. Grant | 20-Jun-2016 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 01-Jan-2015 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 15-Dec-2014 | $7.45M | $7.45M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 01-Jul-2013 | Completed | Clinical Trials - Phase 1 |
Cristal Therapeutics Comparisons
Industry
Financing
Details
Cristal Therapeutics Competitors (104)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytImmune Sciences | Private Equity-Backed | Rockville, MD | ||||
| AnTolRx | Venture Capital-Backed | Cambridge, MA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| TILT Biotherapeutics | Venture Capital-Backed | Helsinki, Finland | ||||
| Nanospectra | Venture Capital-Backed | Houston, TX |
Cristal Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cristal Therapeutics Patents
Cristal Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210395216-A1 | Thiocycloheptyne derivatives and their use | Active | 13-Jul-2018 | ||
| EP-3820858-A1 | Thiocycloheptyne derivatives and their use | Pending | 13-Jul-2018 | ||
| US-12054471-B2 | Thiocycloheptyne derivatives and their use | Active | 13-Jul-2018 | ||
| EP-3377047-A1 | Nanoparticles with active targeting | Inactive | 20-Nov-2015 | ||
| US-20190298855-A1 | Nanoparticles with active targeting | Inactive | 20-Nov-2015 | A61K9/5192 |
Cristal Therapeutics Executive Team (9)
| Name | Title | Board Seat |
|---|---|---|
| Cristianne Rijcken Ph.D | Co-Founder & Chief Scientific Officer | |
| Werner Cautreels Ph.D | Chief Executive Officer & Board Member |
Cristal Therapeutics Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Marcel Kloosterman Ph.D | Brightlands Venture Partners | Supervisory Board Member | |
| Mark Krul Ph.D | Aglaia Oncology Funds | Board Member | |
| Werner Cautreels Ph.D | Self | Chief Executive Officer & Board Member |
Cristal Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cristal Therapeutics Investors (22)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aglaia Oncology Funds | Venture Capital | Minority | ||
| Brabantse Ontwikkelings Maatschappij | Venture Capital | Minority | ||
| Droia Ventures | Venture Capital | Minority | ||
| Limburg Business Development Fund | Venture Capital | Minority | ||
| Horizon 2020 SME Instrument | Government |
Cristal Therapeutics FAQs
-
When was Cristal Therapeutics founded?
Cristal Therapeutics was founded in 2011.
-
Who is the founder of Cristal Therapeutics?
Cristianne Rijcken Ph.D and Joost Holhuis Ph.D are the founders of Cristal Therapeutics.
-
Who is the CEO of Cristal Therapeutics?
Werner Cautreels Ph.D is the CEO of Cristal Therapeutics.
-
Where is Cristal Therapeutics headquartered?
Cristal Therapeutics is headquartered in Maastricht, Netherlands.
-
What is the size of Cristal Therapeutics?
Cristal Therapeutics has 7 total employees.
-
What industry is Cristal Therapeutics in?
Cristal Therapeutics’s primary industry is Drug Discovery.
-
Is Cristal Therapeutics a private or public company?
Cristal Therapeutics is a Private company.
-
What is Cristal Therapeutics’s current revenue?
The current revenue for Cristal Therapeutics is .
-
How much funding has Cristal Therapeutics raised over time?
Cristal Therapeutics has raised $20.9M.
-
Who are Cristal Therapeutics’s investors?
Aglaia Oncology Funds, Brabantse Ontwikkelings Maatschappij, Droia Ventures, Limburg Business Development Fund, and Horizon 2020 SME Instrument are 5 of 22 investors who have invested in Cristal Therapeutics.
-
Who are Cristal Therapeutics’s competitors?
CytImmune Sciences, AnTolRx, NexImmune, TILT Biotherapeutics, and Nanospectra are some of the 104 competitors of Cristal Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
